Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
2007 · Retrovirology · 91 citations
https://doi.org/10.1186/1742-4690-4-89
M
Michael Roche
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
75
Papers
1.9K
Citations
28
h-index
44
i10-index
Michael Roche is an academic researcher from The University of Melbourne. The author has contributed to research in topics: HIV Research and Treatment & HIV/AIDS drug development and treatment & HIV/AIDS Research and Interventions. The author has an h-index of 28, co-authored 64 publications.
ORCID: 0000-0001-8819-0096Papers by this author
worksi-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4
2016 · Journal of Biological Chemistry · 65 citations
https://doi.org/10.1074/jbc.m116.721050
The role of oxidative stress in HIV-associated neurocognitive disorders
2021 · Brain Behavior & Immunity - Health · 51 citations
https://doi.org/10.1016/j.bbih.2021.100235
Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency
2021 · EBioMedicine · 47 citations
https://doi.org/10.1016/j.ebiom.2021.103241
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
2011 · Retrovirology · 42 citations
https://doi.org/10.1186/1742-4690-8-89
The role of latency reversal in <scp>HIV</scp> cure strategies
2022 · Journal of Medical Primatology · 34 citations
https://doi.org/10.1111/jmp.12613
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat